Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis
Errata to this article were published (Nat Med, Dec 2023 ↗ · Mar 2024 ↗)
Authors' conclusion
Altogether, our results highlight that thymic alterations are associated with incidence and seriousness of ICI myotoxicities.
Study context
- Population
- Patients treated with immune checkpoint inhibitors
- Exposure
- Immune checkpoint inhibitors (ICI)-treated thymic epithelial tumours vs other ICI-treated cancers
- Outcome
- ICI myotoxicities (myocarditis, myositis)
Methodological detailspharmacovigilance, data warehouse and registry analyses with meta-analysis of clinical trials, international pharmacovigilance database (VigiBase), hospital data warehouse, international ICI myocarditis registry
- Pharmacovigilance, data warehouse and registry analyses with meta-analysis of clinical trials
- International pharmacovigilance database (VigiBase)
- Hospital data warehouse
- International ICI myocarditis registry
Main finding
As reported in the abstract
- ICI myotoxicities more frequent with TET (particularly thymoma) than other ICI-treated cancers
- ICI myocarditis occurred earlier after ICI initiation with TET
- ICI myocarditis more severe with TET: life-threatening arrhythmias, concurrent myositis leading to respiratory muscle failure and death
- Anti-acetylcholine-receptor antibodies more prevalent in ICI myocarditis than ICI-treated controls
Observational data: associations, not effects.
Original publication
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med. Published 26 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →